Tellgen(SZ:300642) Zheng Quan Shi Bao Wang·2025-10-23 13:21Core Viewpoint - The company,透景生命, has invested 68 million yuan in 惠和生物, acquiring a 9.21% stake, aligning with its strategic focus on the full chain of autoimmune disease management from diagnosis to treatment [1][2]. Investment Details - The investment of 68 million yuan is aimed at supporting 惠和生物's development of innovative treatments for tumors and autoimmune diseases, particularly through its CC312 pipeline, which has shown promising clinical efficacy [1][2]. - The pre-investment valuation of 惠和生物 was set at 670 million yuan, with the post-investment valuation rising to 738 million yuan [2]. Financial Impact - The investment will not affect the company's daily operations or harm the interests of shareholders, and it is not expected to significantly impact the company's performance in 2025 [3]. - In the third quarter of 2025, the company reported a revenue of 98.55 million yuan, a year-on-year decrease of 6.36%, and a net profit of 3.02 million yuan, down 83.02% [3].